Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, et al. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Prostate Most cancers Prostat Dis. 2022;25:65–70.
Dekalo S, Kuten J, Mintz I, Fahoum I, Gitstein G, Keizman D, et al. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate most cancers sufferers with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Most cancers Prostat Dis. 2021;24:910–6.
Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A The position of 68Ga-PSMA-I&T PET/CT within the pretreatment staging of main prostate most cancers. Nuclear Medication Communications [Internet]. 2017;38. Accessible from: https://journals.lww.com/nuclearmedicinecomm/fulltext/2017/11000/the_role_of_68ga_psma_i_t_pet_ct_in_the.10.aspx.
Emmett et al. 2022 The PRIMARY Rating Utilizing intra-prostatic PSMA PET.pdf.
Ditonno F, Franco A, Manfredi C, Veccia A, Valerio M, Bukavina L, et al. Novel non-MRI imaging methods for main analysis of prostate most cancers: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT. Prostate Most cancers Prostatic Dis. 2023.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in sufferers with high-risk prostate most cancers earlier than curative-intent surgical procedure or radiotherapy (proPSMA): a potential, randomised, multicentre examine. Lancet. 2020;395:1208–16.
Mottet N, van den Bergh RCN, Briers E, den Broeck TV, Cumberbatch MG, Santis MD, et al. EAU-EANM-ESTRO-ESUR-SIOG Pointers on Prostate Most cancers—2020 Replace. Half 1: Screening, Prognosis, and Native Remedy with Healing Intent. Eur Urol. 2021;79:243–62.
Web page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 assertion: an up to date guideline for reporting systematic critiques. BMJ. 2021;372:n71.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a software for assessing threat of bias in non-randomised research of interventions. BMJ. 2016;355:i4919.
Brauchli D, Singh D, Chabert C, Somasundaram A, Collie L. Tumour-capsule interface measured on 18F-DCFPyL PSMA positron emission tomography/CT imaging corresponding to multi-parametric MRI in predicting extra-prostatic extension of prostate most cancers at preliminary staging. J Med Imaging Radiat. Oncol. 2020;64:829–38.
Rajwa P, Pfister D, Rieger C, Heidenreich J, Drzezga A, Persigehl T, et al. Significance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in sufferers handled with salvage radical prostatectomy for radiorecurrent prostate most cancers. Prostate. 2023;83:385–91.
Harsini S, Fallahi B, Karamzade Ziarati N, Razi A, Amini E, Emami-Ardekani A, et al. A Potential Examine on [(68)Ga]-PSMA PET/CT Imaging in Newly Identified Intermediate- and Excessive-Threat Prostate Most cancers. Asia Ocean J Nucl. Med Biol. 2021;9:101–10.
Grubmüller B, Baltzer P, Hartenbach S, D’Andrea D, Helbich TH, Haug AR, et al. PSMA Ligand PET/MRI for Major Prostate Most cancers: Staging Efficiency and Medical Impression. Clin. Most cancers Res 2018;24:6300–7.
Muehlematter UJ, Burger IA, Becker AS, Schawkat Ok, Hötker AM, Reiner CS, et al. Diagnostic Accuracy of Multiparametric MRI versus (68)Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Sufferers with Prostate Most cancers. Radiology. 2019;293:350–8.
Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate most cancers detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015;75:1934–40.
Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, et al. (68)Ga-PSMA PET/CT for Major Lymph Node and Distant Metastasis NM Staging of Excessive-Threat Prostate Most cancers. J Nucl Med 2021;62:214–20.
Kubilay E, Akpinar Ç, Oǧuz ES, Araz MS, Soydal Ç, Baltacı S, et al. Significance of metabolic tumor quantity and whole lesion uptake measured utilizing Ga-68 labelled prostate-specific membrane antigen PET/CT in main staging of prostate most cancers. Urol Oncol. 2022;40:408.e19–408.e25.
Moreira LF, Mussi TC, Cunha MLda, Filippi RZ, Baroni RH. Accuracy of (68)Ga-PSMA PET/CT for lymph node and bone main staging in prostate most cancers. Urol. Oncol. 2022;40:104.e17–104.e21.
Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, et al. A Potential Comparability of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Entire-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Conventional Imaging in Major Distant Metastasis Staging of Prostate Most cancers (PROSTAGE). Eur Urol Oncol. 2021;4:635–44.
Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, et al. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography In contrast with Typical Imaging for Preliminary Staging of Remedy-naïve Intermediate- and Excessive-risk Prostate Most cancers: A Retrospective Single-center Examine. Eur. Urol. Oncol. 2022;5:544–52.
Dyrberg E, Hendel HW, Huynh THV, Klausen TW, Løgager VB, Madsen C, et al. 68Ga-PSMA-PET/CT compared with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in sufferers with prostate most cancers: a potential diagnostic accuracy examine. Eur. Radio. 2019;29:1221–30.
Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, et al. 68Ga-PSMA PET/CT Changing Bone Scan within the Preliminary Staging of Skeletal Metastasis in Prostate Most cancers: A Fait Accompli? Clin Genitourin Most cancers 2018;16:392–401.
Zacho HD, Ravn S, Afshar-Oromieh A, Fledelius J, Ejlersen JA, Petersen LJ. Added worth of 68Ga-PSMA PET/CT for the detection of bone metastases in sufferers with newly recognized prostate most cancers and a earlier 99mTc bone scintigraphy. EJNMMI Res 2020;10:31.
Madsen C, Østergren P, Haarmark C. The Worth of 68Ga-PSMA PET/CT Following Equivocal 18F-NaF PET/CT in Prostate Most cancers Sufferers. Diagnostics. 2020;10:352.
Mattoni S, Farolfi A, Formaggio F, Bruno G, Caroli P, Cerci JJ, et al. PSMA PET for the Analysis of Liver Metastases in Castration-Resistant Prostate Most cancers Sufferers: A Multicenter Retrospective Examine. Cancers (Basel). 2022;14:5680.
Bauckneht M, Checcucci E, Cisero E, Rizzo A, Racca M, De Cillis S, et al. The prognostic position of next-generation imaging-driven upstaging in newly recognized prostate most cancers sufferers. Eur. J. Nucl. Med Mol. Imaging 2024;51:864–70.
Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RDA, et al. A potential randomized multicentre examine of the influence of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate most cancers previous to curative-intent surgical procedure or radiotherapy (proPSMA examine): scientific trial protocol. BJU Int 2018;122:783–93.
Koerber SA, Stach G, Kratochwil C, Haefner MF, Rathke H, Herfarth Ok, et al. Lymph Node Involvement in Remedy-Naïve Prostate Most cancers Sufferers: Correlation of PSMA PET/CT Imaging and Roach Method in 280 Males in Radiotherapeutic Administration. J Nucl Med 2020;61:46–50.
Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head Comparability of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Typical Imaging Modalities for Preliminary Staging of Intermediate- to Excessive-risk Prostate Most cancers: A Systematic Evaluate and Meta-analysis. Eur Urol. 2023;84:36–48.
Grünig H, Maurer A, Thali Y, Kovacs Z, Strobel Ok, Burger IA, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective analysis of the distribution, frequency, and quantitative parameters of a possible pitfall in prostate most cancers imaging. Eur J Nucl Med Mol Imaging. 2021;48:4483–94.
Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, et al. A Potential Comparability of (18)F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Entire-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Conventional Imaging in Major Distant Metastasis Staging of Prostate Most cancers (PROSTAGE). Eur Urol Oncol. 2021;4:635–44.
Arslan A, Karaarslan E, Güner AL, Sağlıcan Y, Tuna MB, Özışık O, et al. Comparability of MRI, PSMA PET/CT, and Fusion PSMA PET/MRI for Detection of Clinically Important Prostate Most cancers. J Comput Help Tomogr. 2021;45:210–7.
Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, et al. Preliminary Expertise of 68Ga-PSMA PET/CT Imaging in Excessive-risk Prostate Most cancers Sufferers Previous to Radical Prostatectomy. Eur. Urol. [Internet] 2016;69:393–6. https://linkinghub.elsevier.com/retrieve/pii/S0302283815005138.
Barbosa ÁRG, Amaral BS, Lourenço DB, Bianco B, Gushiken FA, Apezzato M, et al. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate most cancers. Einstein (Sao Paulo). 2022;20:eAO6599.
Chen M, Zhang Q, Zhang C, Zhao X, Marra G, Gao J, et al. Mixture of (68)Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Important Prostate Most cancers: A Lesion-by-Lesion Evaluation. J Nucl Med 2019;60:944–9.
Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, et al. Major lymph-node staging with (68)Ga-PSMA PET in high-risk prostate most cancers: pathologic correlation with prolonged pelvic lymphadenectomy specimens. Urol Oncol. 2021;39:494.e1–e6.
Dekalo S, Kuten J, Campbell J, Mintz I, Bar-Yosef Y, Keizman D., et al. (68)Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for sufferers with favorable intermediate-risk prostate most cancers.Can Urol Assoc J. 2022;16:E381–5.
Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Esler R, et al. Improved specificity with (68)Ga PSMA PET/CT to detect clinically vital lesions “invisible” on multiparametric MRI of the prostate: a single establishment comparative evaluation with radical prostatectomy histology. Eur J Nucl Med Mol Imaging 2019;46:20–30.
Dyrberg E, Hendel HW, Huynh THV, Klausen TW, Løgager VB, Madsen C., et al. 68)Ga-PSMA-PET/CT compared with (18)F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in sufferers with prostate most cancers: a potential diagnostic accuracy examine. Eur Radiol.2019;29:1221–30.
El Hajj A, Yacoub B, Mansour M, Khauli R, Bulbul M, Nassif S, et al. Diagnostic efficiency of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and excessive threat prostate most cancers. Med (Balt.) 2019;98:e17491.
Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, et al. How correct is (68)Gallium-prostate particular membrane antigen positron emission tomography / computed tomography ((68)Ga-PSMA PET/CT) on main lymph node staging earlier than radical prostatectomy in intermediate and excessive threat prostate most cancers? A examine of patient- and lymph node- primarily based analyses. Urol Oncol. 2022;40:6.e1–e9.
Esen T, Falay O, Tarim Ok, Armutlu A, Koseoglu E, Kilic M. et al. (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Major Lymph Node Staging Earlier than Radical Prostatectomy: Central Evaluate of Imaging and Comparability with Histopathology of Prolonged Lymphadenectomy. Eur Urol Focus.2021;7:288–93.
Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, et al. Preliminary expertise with dosimetry, response and affected person reported final result after 177Lu-PSMA-617 remedy for metastatic castration-resistant prostate most cancers. Oncotarget. 2017;8:3581–90.
Frumer M, Milk N, Rinott Mizrahi G, Bistritzky S, Sternberg I, Leibovitch I, et al. A comparability between (68)Ga-labeled prostate-specific membrane antigen-PET/CT and multiparametric MRI for excluding regional metastases previous to radical prostatectomy. Abdom Radio (NY) 2020;45:4194–201.
Gao J, Zhang C, Zhang Q, Fu Y, Zhao X, Chen M, et al. Diagnostic efficiency of (68)Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate most cancers with whole-mount sections. Eur J Nucl Med Mol Imaging 2019;46:1531–41.
Gupta M, Choudhury PS, Hazarika D, Rawal S. A Comparative Examine of (68)Gallium-Prostate Particular Membrane Antigen Positron Emission Tomography-Computed Tomography and Magnetic Resonance Imaging for Lymph Node Staging in Excessive Threat Prostate Most cancers Sufferers: An Preliminary Expertise. World J Nucl Med. 2017;16:186–91.
Gupta M, Choudhury PS, Rawal S, Goel HC, Talwar V, Singh A, et al. Preliminary threat stratification and staging in prostate most cancers with prostatic-specific membrane antigen positron emission tomography/computed tomography: A primary-stop-shop. World J Nucl Med. 2018;17:261–9.
Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. (68)Ga-PSMA Positron Emission Tomography/Computed Tomography Gives Correct Staging of Lymph Node Areas Previous to Lymph Node Dissection in Sufferers with Prostate Most cancers. Eur Urol. 2016;70:553–7.
Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, et al. Prostate-Particular Membrane Antigen PET/CT Mixed with Sentinel Node Biopsy for Major Lymph Node Staging in Prostate Most cancers. J Nucl Med. 2020;61:540–5.
Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, et al. 68Ga-Prostate-Particular Membrane Antigen Positron Emission Tomography-Computed Tomography-Based mostly Major Staging and Histological Correlation after Prolonged Pelvic Lymph Node Dissection in Intermediate-Threat Prostate Most cancers. Urol Int. [Internet] 2021;106:56–62. https://www.karger.com/Article/FullText/515651.
Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, et al. (68)Ga-PSMA PET/CT primarily based main staging and histological correlation after prolonged pelvic lymph node dissection at radical prostatectomy. World J Urol. 2020;38:3085–90.
Kulkarni SC, Sundaram PS, Padma S. In main lymph nodal staging of sufferers with high-risk and intermediate-risk prostate most cancers, how important is the position of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? Nucl Med Commun. 2020;41:139–46.
Kumar S, Singh H, Das CK, Kumar R, Mittal BR. Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT. Clin Nucl Med 2021;46:e268–9.
Kwan TN, Spremo S, Teh AYM, McHarg D, Thangasamy I, Woo HH. Efficiency of Ga-68 PSMA PET/CT for analysis and grading of native prostate most cancers. Prostate Int 2021;9:107–12.
Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, et al. (68)Ga-PSMA PET/CT Changing Bone Scan within the Preliminary Staging of Skeletal Metastasis in Prostate Most cancers: A Fait Accompli? Clin Genitourin Most cancers 2018;16:392–401.
Liu C, Liu T, Zhang Z, Zhang N, Du P, Yang Y, et al. (68)Ga-PSMA PET/CT Mixed with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Important Prostate Most cancers in Males with Earlier Damaging Biopsy Outcomes. J Nucl Med 2020;61:1314–9.
Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, et al. Potential Analysis of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Major Prostate Most cancers Prognosis. Eur Urol Focus 2021;7:764–71.
Rogasch JM, Money H, Zschaeck S, Elezkurtaj S, Brenner W, Hamm B, et al. Ga-68-PSMA PET/CT in treatment-naïve sufferers with prostate most cancers: Which scientific parameters and threat stratification programs finest predict PSMA-positive metastases? Prostate. 2018.
Thalgott M, Düwel C, Rauscher I, Heck MM, Haller B, Gafita A, et al. One-Cease-Store Entire-Physique (68)Ga-PSMA-11 PET/MRI In contrast with Medical Nomograms for Preoperative T and N Staging of Excessive-Threat Prostate Most cancers. Nucl Med. 2018;59:1850–6.
van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, et al. Gallium-68-prostate-specific membrane antigen ((68) Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts full biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate most cancers. BJU Int. 2019;124:62–8.
von Klot CAJ, Merseburger AS, Böker A, Schmuck S, Ross TL, Bengel FM, et al. (68)Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Previous to Radical Prostatectomy in Sufferers with Prostate Most cancers. Nucl Med Mol Imaging 2017;51:314–22.
Yilmaz B, Turkay R, Colakoglu Y, Baytekin HF, Ergul N, Sahin S, et al. Comparability of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI outcomes with postoperative histopathology of prostate most cancers. Prostate. 2019;79:1007–17.
Zacho HD, Ravn S, Afshar-Oromieh A, Fledelius J, Ejlersen JA, Petersen LJ. Added worth of (68)Ga-PSMA PET/CT for the detection of bone metastases in sufferers with newly recognized prostate most cancers and a earlier (99m)Tc bone scintigraphy. EJNMMI Res. 2020;10:31.
Zhang J, Shao S, Wu P, Liu D, Yang B, Han D, et al. Diagnostic efficiency of (68)Ga-PSMA PET/CT within the detection of prostate most cancers previous to preliminary biopsy: comparability with cancer-predicting nomograms. Eur J Nucl Med Mol Imaging 2019;46:908–20.
Zhou C, Tang Y, Deng Z, Yang J, Zhou M, Wang L, et al. Comparability of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate most cancers. EJNMMI Res 2022;12:10.
